An Open-Label Crenezumab Study in Patients With Alzheimer's Disease (CREAD OLE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03491150|
Recruitment Status : Completed
First Posted : April 9, 2018
Last Update Posted : December 4, 2019
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: Crenezumab (RO5490245)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||149 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Open Label Extention (OLE)|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease|
|Actual Study Start Date :||April 11, 2018|
|Actual Primary Completion Date :||May 31, 2019|
|Actual Study Completion Date :||May 31, 2019|
Participants will receive intravenous (IV) Crenezumab.
Drug: Crenezumab (RO5490245)
Crenezumab will be administed by IV, 60 mg/kg every 4 weeks.
- Percentage of Participants With Adverse Events (AEs) [ Time Frame: Baseline to end of study (approximately 5 years). ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03491150
|Study Director:||Clinical Trials||Hoffmann-La Roche|